Lawrence D. Wagman, MD, FACS, executive medical director of St. Joseph’s Hospital, discusses the future of precision medicine and genetic testing in the community.<br />
Lawrence D. Wagman, MD, FACS, executive medical director of St. Joseph’s Hospital, discusses the future of precision medicine and genetic testing in the community.
Wagman says that he would like to see a separation between data that might be interesting in the future, from data that will have immediate impact on treatment or access to clinical trials. Real-world application remains of the upmost important to community oncologists who must integrate these protocols into their day-to-day routines.
Community physicians need to be more careful about explaining what genetic risk means to their patients, says Wagman. It is important that the patient understands the difference between a 1% risk and an 80% risk. He adds that he would also like to see more consistency in reporting from genetic testing companies.
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More